Integrated Positron Emission Tomography - Computed Tomography (PET-CT) in Patients With Pancreatic Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00885248|
Recruitment Status : Unknown
Verified April 2009 by Asan Medical Center.
Recruitment status was: Active, not recruiting
First Posted : April 21, 2009
Last Update Posted : April 21, 2009
In suspecting pancreatic cancer, dynamic phase pancreatic CT is the most effective tool in diagnosis and staging. In addition, magnetic resolution image, endoscopic ultrasonography, endoscopic retrograde pancreatography, angiography can be performed.
After introduction of functional image, PET has been suggested in the role of diagnosis and staging of pancreatic cancer. Furthermore, recently fused images of PET and CT were available.
In this study, the researchers evaluate the role of integrated PET-CT in patients with pancreatic cancer and analysis the cost-effectiveness of the integrated PET-CT.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||70 participants|
|Official Title:||Clinical Implication of Integrated PET-CT in the Patients With Pancreatic Cancer|
|Study Start Date :||January 2009|
|Estimated Primary Completion Date :||November 2009|
|Estimated Study Completion Date :||December 2009|
- Staging of pancreatic cancer [ Time Frame: 6 months after study start ]
- Diagnosis of pancreatic cancer [ Time Frame: 6 months after study start ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00885248
|Korea, Republic of|
|Asan Medical Center|
|Seoul, Korea, Republic of, 138-736|